259 related articles for article (PubMed ID: 31309879)
21. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
[TBL] [Abstract][Full Text] [Related]
22. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
23. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.
Mastoraki A; Schizas D; Charalampakis N; Naar L; Ioannidi M; Tsilimigras D; Sotiropoulou M; Moris D; Vassiliu P; Felekouras E
Mol Diagn Ther; 2020 Apr; 24(2):175-184. PubMed ID: 32125662
[TBL] [Abstract][Full Text] [Related]
24. The role of histone deacetylases in embryonic development.
Dsilva P; Pai P; Shetty MG; Babitha KS
Mol Reprod Dev; 2023 Jan; 90(1):14-26. PubMed ID: 36534913
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylases: target enzymes for cancer therapy.
Mottet D; Castronovo V
Clin Exp Metastasis; 2008; 25(2):183-9. PubMed ID: 18058245
[TBL] [Abstract][Full Text] [Related]
27. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
28. Deacetylation of Transcription Factors in Carcinogenesis.
Halasa M; Adamczuk K; Adamczuk G; Afshan S; Stepulak A; Cybulski M; Wawruszak A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769241
[TBL] [Abstract][Full Text] [Related]
29. Histone acetylation: plants and fungi as model systems for the investigation of histone deacetylases.
Graessle S; Loidl P; Brosch G
Cell Mol Life Sci; 2001 May; 58(5-6):704-20. PubMed ID: 11437232
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Colarossi L; Memeo L; Colarossi C; Aiello E; Iuppa A; Espina V; Liotta L; Mueller C
Proteomics Clin Appl; 2014 Dec; 8(11-12):924-31. PubMed ID: 25091122
[TBL] [Abstract][Full Text] [Related]
31. Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
Gatla HR; Muniraj N; Thevkar P; Yavvari S; Sukhavasi S; Makena MR
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841513
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.
Parbin S; Kar S; Shilpi A; Sengupta D; Deb M; Rath SK; Patra SK
J Histochem Cytochem; 2014 Jan; 62(1):11-33. PubMed ID: 24051359
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
[TBL] [Abstract][Full Text] [Related]
34. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylases and cancer.
Barneda-Zahonero B; Parra M
Mol Oncol; 2012 Dec; 6(6):579-89. PubMed ID: 22963873
[TBL] [Abstract][Full Text] [Related]
36. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in the treatment for multiple myeloma.
Hideshima T; Anderson KC
Int J Hematol; 2013 Mar; 97(3):324-32. PubMed ID: 23475757
[TBL] [Abstract][Full Text] [Related]
39. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
Zhao J; Gray SG; Greene CM; Lawless MW
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
